Supplementary Figures 1 - 9 from Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S1. Serial MRI imaging and lung histopathology analyses show rapid tumor progression of mutant EGFR-driven tumorigenesis in Mig6-/- background. Supplementary Figure S2. Representative photomicrographs of CC10rtTA/EGFRL858R/Mig6+/- mouse lungs at early stages of doxycycline treatment show variability of tumor progression. Supplementary Figure S3. Rapid progression of tumorigenesis 7 days after doxycycline induction of mutant EGFR in Mig6-/- mice. Supplementary Figure S4. No loss of heterozygosity (LOH) in lung tumors of Mig6+/- mice. Supplementary Figure S5. QPCR analysis of mRNA expression in lung tumor samples from Mig6+/+, Mig6+/-, and Mig6-/- mice. Supplementary Figure S6. QPCR analysis of mRNA expression in lung samples from Mig6+/+, Mig6+/-, and Mig6-/- mice at early stages of doxycycline treatment. Supplementary Figure S7. MS and MS/MS spectra of Y394/395 containing tryptic peptide identified in MIG6 (gene symbol ERRFI1). Supplementary Figure S8. Specificity of monoclonal antibodies made against wild type and mutant EGFRs. Supplementary Figure S9. Co-localization of (A-B) MIG6 and EEA1, a marker of early endosomes with both WT EGFR and EGFRL858R and (C-D) LAMP1, a late endosomal marker with WT EGFR, but not EGFRL858R.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362616417